Chargement en cours...
Azeliragon ameliorates Alzheimer's disease via the Janus tyrosine kinase and signal transducer and activator of transcription signaling pathway
OBJECTIVES: TTP488, an antagonist of the receptor for advanced glycation end-products, was evaluated as a potential treatment for patients with mild-to-moderate Alzheimer’s disease (AD). However, the mechanism underlying the protective action of TTP488 against AD has not yet been fully explored. MET...
Enregistré dans:
| Publié dans: | Clinics (Sao Paulo) |
|---|---|
| Auteurs principaux: | , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Faculdade de Medicina / USP
2021
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7920406/ https://ncbi.nlm.nih.gov/pubmed/33681944 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.6061/clinics/2021/e2348 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|